Thank you, your post answered one of my few remaining questions regarding the upper end of B dosage. I hope it is safe to say that the expectations for it to be successful (to possibly varying degrees) across all areas of treatment in terms of safety and efficacy are now extremely high.

Testing has proved it is safe at the dosages tested to date, these dosages work against one of, if not the most, complex viruses seen to date, it appears to have excellent anti-systemic buildup, and it has worked in human patients against all types of tissues. Lung results will highlight its anti-inflammatory properties IMO. Pretty much runs the table as to what IPIX was hoping to establish thru the govt testing process associated w/ CV19.

Writing seems to be on the wall that we do have the major winner in Brilacidin so many of us have expected to see all these many years.

The only real question now remaining is to see just how widespread its uses will be in medicine. We seem to be getting new ones on a regular basis lately.